Skip to main content
Top
Published in:

26-12-2023 | Heart Failure | Original Contribution

Stimulating cardiac glucose oxidation lessens the severity of heart failure in aged female mice

Authors: Qiuyu Sun, Cory S. Wagg, Berna Güven, Kaleigh Wei, Amanda A. de Oliveira, Heidi Silver, Liyan Zhang, Ander Vergara, Brandon Chen, Nathan Wong, Faqi Wang, Jason R. B. Dyck, Gavin Y. Oudit, Gary D. Lopaschuk

Published in: Basic Research in Cardiology | Issue 1/2024

Login to get access

Abstract

Heart failure is a prevalent disease worldwide. While it is well accepted that heart failure involves changes in myocardial energetics, what alterations that occur in fatty acid oxidation and glucose oxidation in the failing heart remains controversial. The goal of the study are to define the energy metabolic profile in heart failure induced by obesity and hypertension in aged female mice, and to attempt to lessen the severity of heart failure by stimulating myocardial glucose oxidation. 13-Month-old C57BL/6 female mice were subjected to 10 weeks of a 60% high-fat diet (HFD) with 0.5 g/L of Nω-nitro-l-arginine methyl ester (L-NAME) administered via drinking water to induce obesity and hypertension. Isolated working hearts were perfused with radiolabeled energy substrates to directly measure rates of myocardial glucose oxidation and fatty acid oxidation. Additionally, a series of mice subjected to the obesity and hypertension protocol were treated with a pyruvate dehydrogenase kinase inhibitor (PDKi) to stimulate cardiac glucose oxidation. Aged female mice subjected to the obesity and hypertension protocol had increased body weight, glucose intolerance, elevated blood pressure, cardiac hypertrophy, systolic dysfunction, and decreased survival. While fatty acid oxidation rates were not altered in the failing hearts, insulin-stimulated glucose oxidation rates were markedly impaired. PDKi treatment increased cardiac glucose oxidation in heart failure mice, which was accompanied with improved systolic function and decreased cardiac hypertrophy. The primary energy metabolic change in heart failure induced by obesity and hypertension in aged female mice is a dramatic decrease in glucose oxidation. Stimulating glucose oxidation can lessen the severity of heart failure and exert overall functional benefits.
Appendix
Available only for authorised users
Literature
7.
go back to reference Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, Yun UJ, Cooksey RC, Litwin SE, Abel ED (2005) Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 146:5341–5349. https://doi.org/10.1210/en.2005-0938CrossRefPubMed Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, Yun UJ, Cooksey RC, Litwin SE, Abel ED (2005) Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 146:5341–5349. https://​doi.​org/​10.​1210/​en.​2005-0938CrossRefPubMed
10.
go back to reference Dyck JR, Cheng J-F, Stanley WC, Barr R, Chandler MP, Brown S, Wallace D, Arrhenius T, Harmon C, Yang G (2004) Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. Circ Res 94:e78–e84CrossRefPubMed Dyck JR, Cheng J-F, Stanley WC, Barr R, Chandler MP, Brown S, Wallace D, Arrhenius T, Harmon C, Yang G (2004) Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. Circ Res 94:e78–e84CrossRefPubMed
16.
go back to reference Holubarsch CJ, Rohrbach M, Karrasch M, Boehm E, Polonski L, Ponikowski P, Rhein S (2007) A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin Sci 113:205–212CrossRef Holubarsch CJ, Rohrbach M, Karrasch M, Boehm E, Polonski L, Ponikowski P, Rhein S (2007) A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin Sci 113:205–212CrossRef
25.
go back to reference Lopaschuk GD (2003) Pharmacologic rationale for trimetazidine in the treatment of ischemic heart disease. Am J Cardiovasc Drugs 3:21–26CrossRef Lopaschuk GD (2003) Pharmacologic rationale for trimetazidine in the treatment of ischemic heart disease. Am J Cardiovasc Drugs 3:21–26CrossRef
28.
go back to reference Lopaschuk GD, Wambolt R, Barr R (1993) An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J Pharmacol Exp Ther 264:135–144PubMed Lopaschuk GD, Wambolt R, Barr R (1993) An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J Pharmacol Exp Ther 264:135–144PubMed
29.
go back to reference Martin C, Schulz R, Rose J, Heusch G (1998) Inorganic phosphate content and free energy change of ATP hydrolysis in regional short-term hibernating myocardium. Cardiovasc Res 39:318–326CrossRefPubMed Martin C, Schulz R, Rose J, Heusch G (1998) Inorganic phosphate content and free energy change of ATP hydrolysis in regional short-term hibernating myocardium. Cardiovasc Res 39:318–326CrossRefPubMed
31.
go back to reference Mori J, Basu R, McLean BA, Das SK, Zhang L, Patel VB, Wagg CS, Kassiri Z, Lopaschuk GD, Oudit GY (2012) Agonist-induced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: a metabolic contribution to heart failure with normal ejection fraction. Circ Heart Fail 5:493–503CrossRefPubMed Mori J, Basu R, McLean BA, Das SK, Zhang L, Patel VB, Wagg CS, Kassiri Z, Lopaschuk GD, Oudit GY (2012) Agonist-induced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: a metabolic contribution to heart failure with normal ejection fraction. Circ Heart Fail 5:493–503CrossRefPubMed
35.
go back to reference Pakiet A, Jakubiak A, Mierzejewska P, Zwara A, Liakh I, Sledzinski T, Mika A (2020) The effect of a high-fat diet on the fatty acid composition in the hearts of mice. Nutrients 12:824CrossRefPubMedPubMedCentral Pakiet A, Jakubiak A, Mierzejewska P, Zwara A, Liakh I, Sledzinski T, Mika A (2020) The effect of a high-fat diet on the fatty acid composition in the hearts of mice. Nutrients 12:824CrossRefPubMedPubMedCentral
36.
go back to reference Pecháňová O, Bernatova I, Pelouch V, Babal P (1999) L-NAME-induced protein remodeling and fibrosis. Physiol Res 48:353–362PubMed Pecháňová O, Bernatova I, Pelouch V, Babal P (1999) L-NAME-induced protein remodeling and fibrosis. Physiol Res 48:353–362PubMed
37.
go back to reference Piao L, Sidhu VK, Fang Y-H, Ryan JJ, Parikh KS, Hong Z, Toth PT, Morrow E, Kutty S, Lopaschuk GD (2013) FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate. J Mol Med (Berl) 91:333–346. https://doi.org/10.1007/s00109-012-0982-0CrossRefPubMed Piao L, Sidhu VK, Fang Y-H, Ryan JJ, Parikh KS, Hong Z, Toth PT, Morrow E, Kutty S, Lopaschuk GD (2013) FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate. J Mol Med (Berl) 91:333–346. https://​doi.​org/​10.​1007/​s00109-012-0982-0CrossRefPubMed
41.
go back to reference Schmidt-Schweda S, Holubarsch C (2000) First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci 99:27–35CrossRef Schmidt-Schweda S, Holubarsch C (2000) First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci 99:27–35CrossRef
45.
go back to reference Stanley WC, Morgan EE, Huang H, McElfresh TA, Sterk JP, Okere IC, Chandler MP, Cheng J, Dyck JR, Lopaschuk GD (2005) Malonyl-CoA decarboxylase inhibition suppresses fatty acid oxidation and reduces lactate production during demand-induced ischemia. Am J Physiol-Heart Circ Physiol 289:H2304–H2309CrossRefPubMed Stanley WC, Morgan EE, Huang H, McElfresh TA, Sterk JP, Okere IC, Chandler MP, Cheng J, Dyck JR, Lopaschuk GD (2005) Malonyl-CoA decarboxylase inhibition suppresses fatty acid oxidation and reduces lactate production during demand-induced ischemia. Am J Physiol-Heart Circ Physiol 289:H2304–H2309CrossRefPubMed
48.
go back to reference Taylor LE, Ramirez LA, Musall JB, Sullivan JC (2019) Tipping the scales: Are females more at risk for obesity-and high-fat diet-induced hypertension and vascular dysfunction? Br J Pharmacol 176:4226–4242CrossRefPubMedPubMedCentral Taylor LE, Ramirez LA, Musall JB, Sullivan JC (2019) Tipping the scales: Are females more at risk for obesity-and high-fat diet-induced hypertension and vascular dysfunction? Br J Pharmacol 176:4226–4242CrossRefPubMedPubMedCentral
49.
go back to reference Taylor M, Wallhaus TR, DeGrado TR, Russell DC, Stanko P, Nickles RJ, Stone CK (2001) An evaluation of myocardial fatty acid and glucose uptake using PET with [18F] fluoro-6-thia-heptadecanoic acid and [18F] FDG in patients with congestive heart failure. J Nucl Med 42:55–62PubMed Taylor M, Wallhaus TR, DeGrado TR, Russell DC, Stanko P, Nickles RJ, Stone CK (2001) An evaluation of myocardial fatty acid and glucose uptake using PET with [18F] fluoro-6-thia-heptadecanoic acid and [18F] FDG in patients with congestive heart failure. J Nucl Med 42:55–62PubMed
52.
go back to reference Ussher JR, Fillmore N, Keung W, Zhang L, Mori J, Sidhu VK, Fukushima A, Gopal K, Lopaschuk DG, Wagg CS (2016) Genetic and pharmacological inhibition of malonyl CoA decarboxylase does not exacerbate age-related insulin resistance in mice. Diabetes 65:1883–1891. https://doi.org/10.2337/db15-1145CrossRefPubMed Ussher JR, Fillmore N, Keung W, Zhang L, Mori J, Sidhu VK, Fukushima A, Gopal K, Lopaschuk DG, Wagg CS (2016) Genetic and pharmacological inhibition of malonyl CoA decarboxylase does not exacerbate age-related insulin resistance in mice. Diabetes 65:1883–1891. https://​doi.​org/​10.​2337/​db15-1145CrossRefPubMed
55.
61.
go back to reference Zhang L, Ussher JR, Oka T, Cadete VJ, Wagg C, Lopaschuk GD (2011) Cardiac diacylglycerol accumulation in high fat-fed mice is associated with impaired insulin-stimulated glucose oxidation. Cardiovasc Res 89:148–156CrossRefPubMed Zhang L, Ussher JR, Oka T, Cadete VJ, Wagg C, Lopaschuk GD (2011) Cardiac diacylglycerol accumulation in high fat-fed mice is associated with impaired insulin-stimulated glucose oxidation. Cardiovasc Res 89:148–156CrossRefPubMed
62.
go back to reference Zhang Y, Taufalele PV, Cochran JD, Robillard-Frayne I, Marx JM, Soto J, Rauckhorst AJ, Tayyari F, Pewa AD, Gray LR (2020) Mitochondrial pyruvate carriers are required for myocardial stress adaptation. Nat Metab 2:1248–1264CrossRefPubMedPubMedCentral Zhang Y, Taufalele PV, Cochran JD, Robillard-Frayne I, Marx JM, Soto J, Rauckhorst AJ, Tayyari F, Pewa AD, Gray LR (2020) Mitochondrial pyruvate carriers are required for myocardial stress adaptation. Nat Metab 2:1248–1264CrossRefPubMedPubMedCentral
Metadata
Title
Stimulating cardiac glucose oxidation lessens the severity of heart failure in aged female mice
Authors
Qiuyu Sun
Cory S. Wagg
Berna Güven
Kaleigh Wei
Amanda A. de Oliveira
Heidi Silver
Liyan Zhang
Ander Vergara
Brandon Chen
Nathan Wong
Faqi Wang
Jason R. B. Dyck
Gavin Y. Oudit
Gary D. Lopaschuk
Publication date
26-12-2023
Publisher
Springer Berlin Heidelberg
Published in
Basic Research in Cardiology / Issue 1/2024
Print ISSN: 0300-8428
Electronic ISSN: 1435-1803
DOI
https://doi.org/10.1007/s00395-023-01020-2

Other articles of this Issue 1/2024

Basic Research in Cardiology 1/2024 Go to the issue

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

Keynote webinar | Spotlight on medication adherence

  • Webinar | 27-06-2024 | 18:00 (CEST)

Medication non-adherence is a major barrier to effective healthcare delivery; half of all patients do not follow their doctor’s recommendations or treatment plan.

Our experts explain the fundamentals with a practical discussion of how to manage non-adherence in two common scenarios: hypertension and asthma control.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Watch now